Cancer Family
Liver Epithelial Neoplasm
CI-CAN-00000217Explore in graph →
Non-malignant784 active trials14 approved drugs17 evidence items
- NCIt
- C7106
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000217Explore in graph →
Clinical trials
3,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06140134 | Liver Transplantation in Intrahepatic Cholangiocarcinoma | recruiting | — | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06345508 | Early Detection of Liver Cancer by QUS(QUS in HCC) | recruiting | — | 328 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 20, 2026 |
| clinicaltrials |
| NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | completed | Phase 3 | 344 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05629845 | Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients(EUS-SPV) | recruiting | N/A | 84 | Chinese University of Hong KongOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06354387 | Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | completed | Phase 1 | 5 | China Medical University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 33 | West China HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483242 | Individualized Surgical Guidance in HCC-BDTT | completed | — | 151 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06077591 | Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors(PDO) | recruiting | N/A | 40 | Chinese University of Hong KongOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07479264 | A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma | completed | — | 169 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07481032 | Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study | not yet recruiting | N/A | 1,034 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Mar 18, 2026 | clinicaltrials |
| NCT05528952 | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma(TERTIO) | recruiting | Phase 2 | 105 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07052253 | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | recruiting | Phase 2 | 100 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01165346 | Stereotaxic Irradiation of Hepatocellular Carcinoma(CKNO-HEP) | completed | Phase 2 | 44 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response | terminated | N/A | 28 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03151213 | Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver(pregabalin) | completed | Phase 4 | 70 | Sherief Abd-ElsalamOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04301778 | Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05901519 | A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06381648 | Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)(LyMIC) | completed | — | 230 | City of Hope Medical CenterOTHER | 2 | Mar 13, 2026 | clinicaltrials |
| NCT07224737 | Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.(EXOMIC) | completed | — | 230 | City of Hope Medical CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07225452 | An Exosomal miRNA-based Liquid Biopsy for ICC Detection(LUMIC) | completed | — | 535 | City of Hope Medical CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05095714 | FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.(FASTRAK) | recruiting | N/A | 944 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07193316 | Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis(SEEK) | completed | — | 38 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06537193 | Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment | recruiting | N/A | 455 | Asan Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | not yet recruiting | Phase 3 | 30 | University of Geneva, SwitzerlandOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | terminated | Phase 3 | 45 | Translational Research in OncologyOTHER | 13 | Mar 9, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05665348 | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy(TRIPLET) | completed | Phase 2 / Phase 3 | 229 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06859684 | Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)(HAIC-quad) | recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06018857 | Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation | active not recruiting | — | 1,000 | Federico AucejoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07454486 | TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort(TRACE-BTC) | not yet recruiting | — | 300 | Aarhus University HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04563338 | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | active not recruiting | Phase 2 | 36 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05432492 | A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 40 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05953337 | Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | active not recruiting | N/A | 120 | ABK BiomedicalINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06885879 | Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma | recruiting | — | 15 | Chinese University of Hong KongOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07449065 | CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC | completed | — | 324 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07449637 | Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma. | not yet recruiting | — | 200 | Sohag UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06218420 | Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation(TRANSRAD-01) | recruiting | Phase 2 | 139 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT06624189 | Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis | enrolling by invitation | — | 1,300 | NYU Langone HealthOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06789848 | Ligufalimab and Cadonilimab in Advanced Liver Cancers | recruiting | Phase 2 | 64 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432347 | Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches(DELIVER) | recruiting | — | 270 | Niguarda HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07436845 | Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy | recruiting | — | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 20, 2026source: clinicaltrials